BioSkryb Genomics Names William E. Evans, Pharm.D. as Chief Executive Officer
CompaniesBioSkryb Genomics
Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
IntraBio’s Pivotal Phase III Trial in CACNA1A-Related Disorders Is Enrolling and Is Expected to Be Over-Enrolled and Complete Recruitment in October
CompaniesIntraBio Inc.AssetslevacetylleucineDiseasesCACNA1A-related disorders
BioMarin spends up to $490m for Alesta’s bone disease candidate
CompaniesBioMarinAlesta TherapeuticsAstraZenecaAssetsALE1Diseaseshypophosphatasia
Related coverage (1) — shares extracted facts, not the same cluster
La FACAF celebra su 40° aniversario
Addressing the Data Gap With Tarlatamab in Brain Metastatic SCLC
CompaniesDuke University School of MedicineAssetstarlatamabDiseasessmall cell lung cancer
Managing Subcutaneous Amivantamab Toxicities in Head and Neck Cancer
AssetsamivantamabDiseaseshead and neck cancer
MAJESTEC-3 Evaluates Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
CompaniesJanssenGlaxoSmithKlineAssetsteclistamabdaratumumabDiseasesrelapsed/refractory multiple myeloma
Weighing Bispecific Antibodies Against CAR T Cells in Multiple Myeloma
Diseasesmultiple myeloma
Expert Discussion on Earlier Use of Teclistamab-Based Therapy in Relapsed/Refractory Multiple Myeloma
Diseasesrelapsed/refractory multiple myeloma
Novel Cancer Vaccine Meets Primary, Secondary End Points in Resected Melanoma
CompaniesMerckAssetsV0940pembrolizumabDiseasesmelanoma
Mente, Corazón y Manos: La Triada de la Salud Digital en la Era de la IA
Cédula digital de salud del IMSS 2026: requisitos, beneficios y formas para conseguirla
Model Medicines Discovers the RdRp Thumb-1 Pocket as a Conserved Target for Broad-Spectrum Antiviral Development
CompaniesModel Medicines
Uso de IAs nas farmácias impulsiona vendas e otimiza processos
CompaniesRetailOn
Stuttering Treatment and Research Society (STARS) Releases First Interdisciplinary Consensus Guidelines on Stuttering
Diseasesstuttering
SFA THERAPEUTICS, INC. ANNOUNCES EXECUTIVE ORGANIZATIONAL CHANGES
CompaniesSFA Therapeutics, Inc.AstraZenecaMayne PharmaceuticalsTemple UniversityAssetsSFA-002DDiseasespsoriasispancreatic cancer
QuadMed's Epic Gold Stars Recognition Signals a New Model for Employer-Sponsored Primary Care
CompaniesQuadMedEpic
Renata Medical Closes $25M Series D Financing Led by Global Healthcare Investment Firm ARCHIMED to Accelerate Commercialization and Development of Pediatric Cardiovascular Technologies
CompaniesRenata MedicalARCHIMEDAssetsMinima Stent SystemDiseasescongenital heart disease
New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence
CompaniesWellspect HealthCare
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
CompaniesBristol Myers SquibbAssetsZENBEXUSdaratumumabhyaluronidase-fihjdexamethasoneDiseasesmultiple myeloma